LSTA

Lisata TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$2.00

Analysis reference price unavailable

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Most likely

Base case

55%

Probability

Target price

$1.00

Analysis reference price unavailable

Analysis 2026-08-08 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$0.45

Analysis reference price unavailable

Analysis 2026-08-08 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-08

AI commentary

News flow is sparse and dominated by the terminated Kuva transaction, ensuing litigation, and workforce reduction. Historical program and partnership commentary provides only a weak long-horizon hook because no current milestone update is available. The stock remains highly event-driven; social, options, short-interest, employee-sentiment, analyst-revision, and post-event target-change data are unavailable, so zero values denote unavailable inputs rather than neutral evidence.

RankAlpha Sentiment Codex - 2026-08-08

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalyst72% workforce reduction and R&D leadership departureHigh impact

Lisata approved an approximately 72% workforce reduction to reduce ongoing expenses while pursuing strategic options; its chief medical officer’s employment was terminated. The company expects about $1.2 million of severance and related costs through September 30, 2026 [#8-K-2026-08-04].

2026-11-06eventDelaware litigation over terminated Kuva mergerHigh impact

Lisata commenced legal action against Kuva and its subsidiary for alleged breach of the merger agreement and is seeking damages. Recovery timing and amount remain uncertain [#8-K-2026-08-04].

2027-08-08catalystStrategic-options processHigh impact

Management is pursuing strategic options after materially reducing the operating footprint. Potential transaction value is highly uncertain, with no disclosed timetable or assurance of an attractive outcome [#8-K-2026-08-04].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-08 • Updated nightlySource: Internal modelMethodology